Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Common Equity (2021 - 2025)

Historic Common Equity for Krystal Biotech (KRYS) over the last 5 years, with Q4 2025 value amounting to $1.2 billion.

  • Krystal Biotech's Common Equity rose 2886.58% to $1.2 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.2 billion, marking a year-over-year increase of 2886.58%. This contributed to the annual value of $1.2 billion for FY2025, which is 2886.58% up from last year.
  • Krystal Biotech's Common Equity amounted to $1.2 billion in Q4 2025, which was up 2886.58% from $1.1 billion recorded in Q3 2025.
  • In the past 5 years, Krystal Biotech's Common Equity ranged from a high of $1.2 billion in Q4 2025 and a low of $408.2 million during Q3 2021
  • In the last 5 years, Krystal Biotech's Common Equity had a median value of $704.5 million in 2023 and averaged $727.6 million.
  • In the last 5 years, Krystal Biotech's Common Equity plummeted by 1201.95% in 2022 and then skyrocketed by 6325.52% in 2024.
  • Over the past 5 years, Krystal Biotech's Common Equity (Quarter) stood at $593.6 million in 2021, then fell by 12.02% to $522.2 million in 2022, then skyrocketed by 49.1% to $778.6 million in 2023, then rose by 21.54% to $946.4 million in 2024, then increased by 28.87% to $1.2 billion in 2025.
  • Its last three reported values are $1.2 billion in Q4 2025, $1.1 billion for Q3 2025, and $1.0 billion during Q2 2025.